• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006

  • — 14 Nov, 2006
AudioMedica News
AudioMedica News
Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006
Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006
00:00 /
RSS Feed
Share
Link
Embed
Theodore Mazzone
Theodore Mazzone
Timothy Gardner
Timothy Gardner
Christopher Cannon
Christopher Cannon

Atherosclerosis Halted in Type 2 Diabetes by Pioglitazone for Glycemic Control

REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract: Late Breaking Trials I, Monday 13th November
THEODORE MAZZONE, University of Illinois, Chicago
The choice of drug for achieving glycemic control in type 2 diabetes has been shown to influence cardiovascular risk as measured by carotid intima thickening. In a study reported to the AHA conference Theodore Mazzone presented results comparing pioglitazone with glimepiride. After his talk in Chicago he discussed his findings with Peter Goodwin.

Pioglitazone and Cardio Risks; Cox-2 Inhibitor Safety

REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract: Lancet Online 13th November, 2006, Late Breaking Clinical Trials I: Monday 13th November
TIMOTHY GARDNER, Christiana Care, Delaware
Timothy Gardner, Program Chair of the American Heart Association Sessions commented on the presentations of Theodore Mazzone and Chris Cannon.

Cox-2 Inhibitor Etoricoxib: No More Risk than Non-Steroidal

American Heart Association Scientific Sessions 2006 November 12-15th Chicago, Illinois. Abstract: LB I
CHRISTOPHER CANNON, Brigham And Women’s Hospital, Boston
One of the Cox-2 inhibitor family of drugs for arthritis – etoricoxib – may have proved itself to affect cardiovascular risks no more than the non-steroidal anti-inflammatory drug, diclofenac. This was announced at the AHA Sessions in Chicago and has been simultaneously published in the Lancet. Christopher Cannon told Sarah Maxwell about his group’s findings in the MEDAL study.

[audio:https://www.audiomedica.com/podcasting/aha/061114Nov13thAHA2ndPodcast.mp3]

You may also like...

  • Cardiac Re-Synchronisation Cuts Sudden Death Cardiac Re-Synchronisation Cuts Sudden Death 12 Sep, 2005
  • Enoxaparin Shows Safety in Angioplasty – STEEPLE Study Enoxaparin Shows Safety in Angioplasty – STEEPLE Study 12 Sep, 2005
  • Audio Journal of Cardiovascular Medicine: September 8th 2006 Audio Journal of Cardiovascular Medicine: September 8th 2006 8 Sep, 2006
  • Europe Leaps to Action on Heart-Unfriendly Lifestyles Europe Leaps to Action on Heart-Unfriendly Lifestyles 12 Sep, 2005
  • Previous story Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006
  • Next story Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • New Front Line Standard for Older Patients with Chronic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Which Tasks Most Influence Pediatric PT Productivity,…
  • Home
  • Cardiovascular
  • Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.